Idexx Laboratories, Inc.

Murthy V S N Yerramilli

Mahalakshmi Yerramilli

Michael Randolph Atkinson

Giosi Farace

Hongzhi Xie

Kwok Kam Yeung

Mahalakshimi Yerramilli

John J Quinn

Daniel Wayne Patch

Dominic Pelletier

Robert W Lachapelle

Evan M Peck

Lucius S Fox

Sreenivasa Rao Ramisetty

Pamela Ann Cacavas

Wendy O'Malley LePage

Eric Allen Steva

Jon Braff

The disclosure provides compositions and methods for the detection of renal disease and periodontal disease in mammals.

Methods and compositions for the detection and diagnosis of renal disease and periodontal disease

A method using a chemical analyzer for removing a component of a liquid sample which may interfere with a test performed on a test assay includes the steps of adding the liquid sample to a sample cup, transferring a volume of the liquid sample to a mixing cup containing an IMAC (Immobilized Metal Affinity Chromatography) resin containing porous beads to form a sample/resin solution in the mixing cup, using a pipette of the chemical analyzer to repeatedly aspirate the sample/resin solution into a disposable pipette tip of the pipette and expelling the sample/resin solution from the pipette tip into the mixing cup to achieve a mixed sample/resin solution in the mixing cup, and allowing the mixed sample/resin solution in the mixing cup to rest undisturbed so that the interfering component of the liquid sample adheres to the porous beads and the beads settle to a bottom portion of the mixing cup, resulting in a refined liquid sample devoid of the interfering component and occupying an upper portion of the mixing cup for later dispensing on the test assay.

Method for removing interfering components of a liquid sample prior to dispensing same on a chemical reagent test slide

This invention provides reagents and methods for diagnosing renal disease. Differential levels of inosine metabolite, and proteins: apolipoprotein C-I, apolipoprotein C-II, fibrinogen alpha chain, or fibrinogen A-alpha chain, kininogen, Inter-Alpha Inhibitor H4 (ITIH4), keratin Type I cytoskeletol 10 cystatin A, cystatin B and other polypeptides and fragments thereof provide biomarkers of renal disease and are described herein.

Markers for renal disease

The disclosure relates generally to methods for measuring bacteria in biological samples. More particularly, the disclosure relates to methods for measuring bacteria using an aqueous clearance solution.

Methods for measuring bacteria in biological samples

Homogeneous immunoassays that allow for compensation of background signals inherent in samples and reagents. The use of homogeneous immunoassays for the detection of the presence or amount of symmetrical Dimethyl Arginine (SDMA) in biological samples. Reagents and kits for conducting the assays.

Homogenous immunoassay with compensation for background signal

The disclosure generally relates to the detection of symmetrical dimethylarginine (SDMA). More particularly, the disclosure relates to the detection of SDMA using a solid phase. The disclosure provides devices, reagents, kits and methods for detecting symmetrical dimethyl arginine (SDMA) in sample, such as a biological sample from an animal. The method includes detecting the presence or amount of SDMA in the sample by using an immunoassay format, such as a competitive immunoassay. The assay includes the use of antibodies to SDMA that are specific for SDMA and that have less affinity for other arginine derivatives.

Detection of symmetrical dimethylarginine

The disclosure is directed to methods and apparatus for the determination, diagnosis, progression and prognosis of kidney disease and mortality associated with kidney disease. The disclosure includes methods for determining renal function, in particular estimating glomerular filtration rate (GFR), in an animal. GFR can be useful in the diagnosis and treatment of kidney disease or dysfunction. In various aspects, the disclosure is directed to the use of free symmetrical dimethylarginine (SDMA) and creatinine in blood samples from animals, in particular cats and dogs, to determine glomerular filtration rate and kidney disease.

Methods for detecting renal disease

Method of detecting Symmetrical dimethyl arginine (SDMA) in biological samples. SDMA analogs for generating anti-SDMA antibodies having little or no cross-reactivity with asymmetrical dimethyl arginine, arginine, and monomethylarginine. The analogs have a protected or free thiol (&#x2014;SH) group or hydroxyl (&#x2014;OH) group that allow them to be linked to a suitable conjugation target which can be, for example, a protein containing molecule of a label. The anti-SDMA antibodies can be used in diagnostic immunoassay for the diagnosis of SDMA associated disorders and/or diseases.

Methods for detecting symmetrical dimethylarginine

A method for determining the amount of NT-proBNP in blood samples from animals. The method includes detecting degradation products of NT-proBNP by various methods, including using antibodies, kits and device.

Growing community of inventors

Falmouth, ME, United States of America

Murthy V S N Yerramilli